



Year: 2017

Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - A systematic review of randomized trials, observational studies and case reports

Croce, Evelina ; Hatz, Christoph ; Jonker, Emile F ; Visser, L G ; Jaeger, Veronika K ; Bühler, Silja

Abstract: **BACKGROUND:** Live vaccines are generally contraindicated on immunosuppressive therapy due to safety concerns. However, data are limited to corroborate this practice. **OBJECTIVES:** To estimate the safety of live vaccinations in patients with immune-mediated inflammatory diseases (IMID) or solid organ transplantation (SOT) on immunosuppressive treatment and in patients after bone-marrow transplantation (BMT). **DATA SOURCES:** A search was conducted in electronic databases (Cochrane, Pubmed, Embase) and additional literature was identified by targeted searches. **ELIGIBILITY CRITERIA:** Randomized trials, observational studies and case reports. **POPULATION:** Patients with IMID or SOT on immunosuppressive treatment and BMT patients <2years after transplantation. **INTERVENTION/VACCINATIONS LOOKED AT** Live vaccinations: mumps, measles, rubella (MMR), yellow fever (YF), varicella vaccine (VV), herpes zoster (HZ), oral typhoid, oral polio, rotavirus, Bacillus Calmette-Guérin (BCG), smallpox. **DATA EXTRACTION:** One author performed the data extraction using pre-defined data fields. It was cross-checked by two other authors. **RESULTS:** 7305 articles were identified and 64 articles were included: 40 on IMID, 16 on SOT and 8 on BMT patients. In most studies, the administration of live vaccines was safe. However, some serious vaccine-related adverse events occurred. 32 participants developed an infection with the vaccine strain; in most cases the infection was mild. However, in two patients fatal infections were reported: a patient with RA/SLE overlap who started MTX/dexamethasone treatment four days after the YFV developed a yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and died. The particular vaccine lot was found to be associated with a more than 20 times risk of YEL-AVD. One infant whose mother was under infliximab treatment during pregnancy received the BCG vaccine at the age of three months and developed disseminated BCG infection and died. An immunogenicity assessment was performed in 43 studies. In most cases the patients developed satisfactory seroprotection rates. In the IMID group, YFV and VV demonstrated high seroconversion rates. MTX and tumor necrosis factor inhibitory therapy appeared to reduce immune responses to VV and HZ vaccine, but not to MMR and YF-revaccination. Seroconversion in SOT and BMT patients showed mostly higher rates for rubella than for measles, mumps and varicella. **LIMITATIONS:** Risk of bias was high in the majority of studies since 39 of them were observational and 17 were case series/case reports. Only eight studies were randomized trials. BMT patient numbers included in this review were low. **CONCLUSIONS:** Although live vaccinations were safe and sufficiently immunogenic in most studies, some serious reactions and vaccine-related infections were reported in immunosuppressed IMID and SOT patients. Apart from mild vaccine-related infections MMR and VV vaccines were safe when administered less than two years after BMT. **IMPLICATIONS OF KEY FINDINGS:** Until further data are available, live vaccinations under most immunosuppressive treatments should only be administered after a careful risk benefit assessment of medications and dosages. **FUNDING:** None.

Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: <https://doi.org/10.5167/uzh-143879>
Journal Article
Accepted Version

Originally published at:

Croce, Evelina; Hatz, Christoph; Jonker, Emile F; Visser, L G; Jaeger, Veronika K; Bühler, Silja (2017). Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - A systematic review of randomized trials, observational studies and case reports. *Vaccine*, 35(9):1216-1226.
DOI: <https://doi.org/10.1016/j.vaccine.2017.01.048>

1 **Title**

2 Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated
3 inflammatory diseases, solid organ transplantation or after bone-marrow transplantation – a
4 systematic review of randomized trials, observational studies and case reports

5

6 **Authors**

7 Evelina Croce ^a

8 Christoph Hatz ^{a,b,c}

9 Emile F. Jonker ^d

10 L. G. Visser ^d

11 Veronika K. Jaeger ^e

12 Silja Bühler ^{a,*}

13

14 a Department of Public Health, Division of Infectious Diseases / Travel Clinic, Epidemiology,
15 Biostatistics and Prevention Institute, Hirschengraben 84, 8001 Zurich, Switzerland. Phone: +41 44
16 634 4631, Fax: +41 44 634 4984

17 b Department of Medicine and Diagnostics, Swiss Tropical and Public Health Institute, Socinstrasse
18 57, 4051 Basel, Switzerland. Phone: +41 61 284 81 11, Fax: +41 61 284 81 01

19 c University of Basel, Switzerland, Petersplatz 1, 4003 Basel, Switzerland, Phone: +41 61 284 81 11,
20 Fax: +41 61 284 81 01

1 c Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands,

2 Phone: +31 71 5262613, Fax: +31 71 5266758

3 e Department of Rheumatology, Basel University Hospital, Petersgraben 4, 4031 Basel, Switzerland.

4 Phone: +41 61 556 50 18, Fax: +41 61 265 90 21

5

6 * Corresponding author

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

1 **Abstract**

2 *Background:* Live vaccines are generally contraindicated on immunosuppressive therapy due to
3 safety concerns. However, data are limited to corroborate this practice.

4 *Objectives:* To estimate the safety of live vaccinations in patients with immune-mediated
5 inflammatory diseases (IMID) or solid organ transplantation (SOT) on immunosuppressive treatment
6 and in patients after bone-marrow transplantation (BMT).

7 *Data Sources:* A search was conducted in electronic databases (Cochrane, Pubmed, Embase) and
8 additional literature was identified by targeted searches.

9 *Eligibility criteria:* Randomized trials, observational studies and case reports.

10 *Population:* Patients with IMID or SOT on immunosuppressive treatment and BMT patients <2 years
11 after transplantation.

12 *Intervention/vaccinations looked at:* Live vaccinations: mumps, measles, rubella (MMR), yellow fever
13 (YF), varicella vaccine (VV), herpes zoster (HZ), oral typhoid, oral polio, rotavirus, Bacillus Calmette–
14 Guérin (BCG), smallpox.

15 *Data extraction:* One author performed the data extraction using predefined data fields. It was cross-
16 checked by two other authors.

17 *Results:* 7,305 articles were identified and 64 articles were included: 40 on IMID, 16 on SOT and 8 on
18 BMT patients. In most studies, the administration of live vaccines was safe. However, some serious
19 vaccine-related adverse events occurred. 32 participants developed an infection with the vaccine
20 strain; in most cases the infection was mild. However, in two patients fatal infections were reported:
21 a patient with RA/SLE overlap who started MTX/dexamethasone treatment four days after the YFV
22 developed a yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and died. The particular
23 vaccine lot was found to be associated with a more than 20 times risk of YEL-AVD. One infant whose
24 mother was under infliximab treatment during pregnancy received the BCG vaccine at the age of
25 three months and developed disseminated BCG infection and died. An immunogenicity assessment

1 was performed in 43 studies. In most cases the patients developed satisfactory seroprotection rates.
2 In the IMID group, YFV and VV demonstrated high seroconversion rates. MTX and tumor necrosis
3 factor inhibitory therapy appeared to reduce immune responses to VV and HZ vaccine, but not to
4 MMR and YF-revaccination. Seroconversion in SOT and BMT patients showed mostly higher rates for
5 rubella than for measles, mumps and varicella.

6 *Limitations:* Risk of bias was high in the majority of studies since 39 of them were observational and
7 17 were case series/case reports. Only eight studies were randomized trials. BMT patient numbers
8 included in this review were low.

9 *Conclusions:* Although live vaccinations were safe and sufficiently immunogenic in most studies,
10 some serious reactions and vaccine-related infections were reported in immunosuppressed IMID and
11 SOT patients. Apart from mild vaccine-related infections MMR and VV vaccines were safe when
12 administered less than two years after BMT.

13 *Implications of key findings:* Until further data are available, live vaccinations under most
14 immunosuppressive treatments should only be administered after a careful risk benefit assessment
15 of medications and dosages.

16 *Funding:* None.

17 **Keywords**

18 Immunosuppressive medication, live vaccine, immune-mediated inflammatory disease, solid organ
19 transplantation, bone-marrow transplantation

20 **Abbreviations**

21 AEs – adverse events, BCG - Bacillus Calmette–Guérin, BMT - bone marrow transplantation, CSA - cyclosporine A, GvHD –
22 graft versus host disease, HZ - herpes zoster, HZV - herpes zoster vaccine, IBD - inflammatory bowel disease, IFX –
23 infliximab, IMID - immune-mediated inflammatory disease, INF – interferon, IVIG – intravenous immunoglobulin, JIA -
24 juvenile idiopathic arthritis, MMF - mycophenolate-mofetil, MMR - mumps; measles; rubella, MS – multiple sclerosis, MTX –
25 methotrexate, RA – rheumatoid arthritis, RCT – randomized controlled trial, RTX – rituximab, SAE – serious adverse event,
26 SLE – systemic lupus erythematosus, SOT – solid organ transplantation, TAC – tacrolimus, TCZ – tocilizumab, TNFi – tumor
27 necrosis factor inhibitor, VV – varicella vaccine, VZV – varicella zoster virus, YEL-AVD - yellow fever vaccine-associated
28 viscerotropic disease, YF – yellow fever, YFV – yellow fever vaccine

29

1 **Introduction**

2

3 Immunizations are an important means for preventing infectious diseases in healthy individuals and
4 especially in vulnerable patient groups with immunocompromising conditions. However, live
5 vaccinations contain an attenuated vaccine strain, which has the theoretical potential to revert to the
6 original pathogenic form and to induce infection by the vaccine strain, particularly in
7 immunocompromised individuals. Serious infections with the vaccine strain and even deaths have
8 occurred in HIV patients, leukemia patients and patients with inherited immunodeficiencies [1–4].

9 The number of individuals treated with immunosuppressive medications due to immune-mediated
10 inflammatory diseases (IMID), solid organ transplantation (SOT) or patients after bone-marrow
11 transplantation (BMT) has grown over the last decades [5]. Clinicians are increasingly exposed to the
12 dilemma on whether an immunosuppressed patient can receive a live vaccine – which is very
13 important as severe infections with infections preventable by live vaccinations such as measles and
14 varicella can occur on immunosuppressive therapy [6,7]. On the other hand, the live vaccine itself
15 may impose a danger to the immunosuppressed individual. Furthermore, vaccines may be less
16 effective when administered to an impaired immune system [8].

17 To date, live vaccines are contraindicated under most immunosuppressive therapies. However, data
18 are generally scarce. Over the last few years efforts have been made to evaluate the safety of some
19 live vaccines in selected immunosuppressed individuals by conducting both, retrospective and
20 prospective studies. Further data have become available as live vaccines were occasionally
21 administered inadvertently or after a careful risk-benefit assessment to individual patients.

22 In this systematic review, we aim to provide an overview on the results of published randomized
23 trials, observational studies and case reports on live vaccinations in patients with IMIDs or SOT on
24 immunosuppressive therapy as well as BMT patients who received a live vaccine less than two years
25 after receiving the BMT. Live vaccines are generally accepted after this 2 year time period in BMT

1 patients if no immunosuppressive therapy is given and no GvHD is present [9]. Our **primary objective**
2 is to examine the **safety** of the live vaccinations (mumps, measles, rubella (MMR), yellow fever (YF),
3 varicella vaccine (VV), herpes zoster (HZ), oral typhoid, oral polio, rotavirus, Bacillus Calmette–Guérin
4 (BCG), smallpox) in patients on immunosuppressive treatment with an IMiD or SOT as well as
5 patients less than two years after BMT. This includes the assessment (i) of systemic or local vaccine
6 reactions (ii) of the risk of infection with the attenuated vaccine strain, and (iii) on whether live
7 vaccinations are associated with relapses/worsening of the underlying disease or organ rejection.
8 Our **secondary objectives** are to examine the **immunogenicity** and the **clinical protection** of live
9 vaccinations in these patients.

10

11

1 **Methods**

2 **Eligibility criteria for study inclusion**

3 **Population:** Patients of any age with an IMID or SOT who were on immunosuppressive treatment at
4 the time of vaccination as well as patients less than two years after BMT were considered. As live
5 vaccines are generally accepted two years after BMT if no immunosuppressive therapy is given and
6 no GvHD is present publications on live vaccines more than two years after BMT were not
7 considered.

8 **Studied Vaccinations:** Live attenuated vaccinations (MMR, YF, VV, HZ, oral typhoid, oral polio,
9 rotavirus, BCG, smallpox).

10 **Outcomes:** Our primary outcome measure is the safety of live vaccinations; this includes the
11 assessment (i) of systemic or local vaccine reactions (ii) of the risk of infection with the attenuated
12 vaccine strain, and (iii) on whether live vaccinations are associated with relapses/worsening of the
13 underlying disease or organ rejection. The secondary outcome measures are the immunogenicity and
14 clinical protection of live vaccinations in patients with the conditions defined above. To assess
15 immunogenicity we included humoral immune responses (antibody concentrations, seroconversion
16 rates) and cellular responses, depending on the available information in the studies. As often no
17 control group was studied we focused on clinical protection and not on efficacy or effectiveness of
18 vaccinations.

19 **Included Study Designs:** Randomized trials, observational studies and case reports.

20 **Information Sources**

21 The Cochrane, Pubmed, Embase databases were searched without applying time restrictions.
22 Unpublished (grey) literature (unpublished reports, conference abstracts) was retrieved through
23 targeted website searches of relevant organizations and international conferences dealing with
24 vaccination, infectious diseases, IMIDs, SOT and BMT, i.e. European League Against Rheumatism,

1 Centers for Disease Control and Prevention, Infectious Diseases Society of America, American College
2 of Rheumatology, European Society for Organ Transplantation, American Society of Transplantation,
3 European Society for Blood and Marrow Transplantation, American Society for Bone Marrow
4 Transplantation. Additional articles were identified through reference lists of selected papers. The
5 search was run on March 23rd 2014. A limited update search was run on January 22nd 2016.

6 **Search** terms were peer reviewed during the development process. The search terms in Figure 1
7 were used in combination to search the databases. Corresponding Medical Subject Headings and
8 Embase subject headings were searched for.

9 **Study selection**

10 Two review authors performed eligibility assessment based on titles, key words, and abstracts
11 independently (SB and VKJ). Disagreements between review authors were resolved by consensus.
12 One review author conducted the eligibility assessment (EC) based on the full article; this was
13 checked by two other review authors (SB and VKJ). If authors published several studies on the same
14 subject (e.g. varicella vaccination in stem cell transplantation) we compared sample sizes, outcomes
15 and time frames of study conduct to avoid double counting.

16 **Data collection process**

17 A data extraction sheet was piloted on five randomly-selected studies and was refined accordingly.
18 Data extraction was performed by one author (EC) and checked by two other authors (SB and VKJ). In
19 case of disagreement, a consensus was sought by discussion between the three authors. In 10 cases,
20 study authors were contacted to receive further/clarifying information. Seven authors answered and
21 in six cases the relevant information could be retrieved. In three cases the author did not respond
22 and it could not be clarified whether the patients were treated with immunosuppressive therapy
23 during the immunization. These three articles were excluded.

24 **Data items**

1 Information from each record was extracted on year of publication, year of study conduct, country,
2 study design, number of participants, enrolment of controls, number of vaccine doses, underlying
3 disease, immunosuppressive medication, primary vaccine dose or secondary/revaccination vaccine
4 doses, vaccine reaction (local or systemic), infection through vaccine strain, flare of underlying
5 disease (IMID) or transplant rejection (SOT/BMT), immunogenicity assessment performed, test for
6 immunogenicity assessment, time point for immunogenicity assessment, results of immunogenicity
7 assessment, clinical protection assessment performed, duration of follow-up for clinical protection,
8 results of clinical protection assessment, conclusion (see supplementary file). If a live vaccine was
9 administered to a seronegative patient it was defined as a “primary vaccination”. If a second
10 vaccination was given or if patients were known to be seropositive at the time of vaccination, the
11 vaccination was defined as “secondary vaccination” or “re-immunization”.

12

13

1 **Results**

2 **Study selection**

3 7,290 articles were identified through database searching and 15 articles were identified through
4 other sources. After removal of duplicates, 7,187 articles remained. 550 articles were left after title
5 and keyword screening and 105 (IMID n=64, BMT n=20, SOT n=21) articles were left after abstract
6 screening (Figure 2). The full-text of these articles were assessed for eligibility and finally 64 articles
7 were included in this systematic review (see supplementary file for details on included studies).

8 Of these, 40 (YF n=9 (n=8 in adults, n=1 in children and adults), MMR n=6 (n=1 in adults, n=5 in
9 children), varicella n=12 (n=3 in adults, n=9 in children, n=1 in children and adults), HZ n=8 (all in
10 adults), polio n=1 (adult), BCG n=4 (n=2 in adults, n=2 in children), live typhoid n=1 (adult), smallpox
11 n=1 (adult)) were conducted in IMID patients. 16 studies (YF n=2 (n=1 in adults, n=1 in children and
12 adults), MMR n=7 (all in children), varicella n=11 (n=2 in adults, n=9 in children), BCG n=1 (children))
13 were identified in SOT patients and eight (MMR n=4 (n=2 in children, n=2 in children and adults),
14 varicella n=5 (n=1 in adults, n=2 in children, n=2 in children and adults)) in BMT patients. Some
15 studies evaluated several live vaccines. No study on rotavirus vaccination was identified. In one study
16 the participants (IMID patients) were vaccinated simultaneously against YF, MMR and varicella. In
17 five studies (SOT patients) the participants were vaccinated against MMR and varicella
18 simultaneously. 41 full-text articles were excluded because patients were not on immunosuppressive
19 therapy at time point of vaccination (IMID or SOT, n=15), administration of live vaccine later than two
20 years after BMT (n=11), no original work (n=12), the results were already presented in other articles
21 (n=2), or because of an additional inherited immunodeficiency of the vaccinated patient (n=1). Out of
22 the 64 included articles, eight were randomized controlled trials (RCTs), 39 observational studies and
23 17 case series/reports. RCTs were only identified in the IMID group (varicella n=5, HZ n=1, YF n=1,
24 MMR n=1).

25 **Study characteristics**

1 A total of 21,082 patients received a live vaccine in the studies, which were published between 1977
2 and 2016. Studies were conducted in 18 different countries including USA (n=18), Brazil (n=13), Japan
3 (n=6) and Germany (n=4). As some patients received several live vaccines concomitantly the
4 presented numbers may not add up.

5 **Immune mediated inflammatory diseases**

6 Most of the patients (n=20,556) had an **IMID**. Of these, 19,630 patients received an HZ, 474 an MMR,
7 233 a YF, 202 a varicella, 10 an oral typhoid, 5 a BCG, one a live poliomyelitis and one a smallpox
8 vaccination.

9 The most frequently represented disease categories in the IMID group are summarized in Table 1.
10 The participants in the IMID group were under 22 different immunosuppressive medications. The
11 most common medication in this group was glucocorticoids (n=384) with a prednisone-equivalent
12 dosage range of 2.5-35mg/day, followed by methotrexate (MTX, n=268) with a dosage range of 5-
13 27mg/m²/week. 98 patients in the IMID group were treated with a combination therapy; 218
14 received a monotherapy with a biological, 39 received a combination therapy with a biological. 633
15 patients received herpes zoster vaccine (HZV) under biological therapy. It was unclear whether this
16 was a mono- or a combination therapy. In this study the medication was only reported in
17 7,780/18,683 patients. So numbers of patients with HZV on immunosuppressive therapy may have
18 been higher [10]. In the IMID group, in 18 studies primary vaccinations were administered, in 13
19 studies secondary doses were given. In six studies a primary and a secondary vaccination were
20 administered and in three studies it was unknown whether a primary or a secondary vaccination was
21 given.

22

23 **SOT**

24 339 **SOT patients** with live vaccinations were identified; 192 were vaccinated against varicella, 172
25 against MMR, 20 against YF, and 24 received the BCG vaccine.

1 Of the 339 SOTs, 271 were liver transplants, 62 kidney transplants, four heart transplants, one small
2 bowel transplant, and one liver and small bowel transplant. The SOT patients were treated with eight
3 different immunosuppressive medications. The most frequently used medication was tacrolimus
4 (TAC, n=134, 2.4-10ng/ml in serum), followed by cyclosporine A (CSA, n=56) with a dosage range
5 from 30-120ug/l; 70 transplanted participants were under a combination therapy. In seven studies
6 patients received a primary vaccination, in one study only revaccinations were given and in eight
7 studies the patients received a primary vaccination as well as a secondary vaccination.

8 **BMT**

9 Only a small part of the participants were **patients with BMT (n=187)**. Of these, 152 received an
10 MMR vaccination and 38 received a VV. The underlying diseases of BMT patients are specified in
11 Table 2. All BMT patients (n=38) who received VV, were not on current immunosuppressive therapy.
12 27 patients who received an MMR immunization were treated with an immunosuppressive therapy
13 at vaccination (CSA n=12, CSA/prednisone n=11; prednisone n=2, mycophenolate-mofetil (MMF)
14 n=2). In one study, seven BMT patients (MMR vaccination n=7, VV n=3) took a calcineurin inhibitor
15 and MMF as graft versus host disease (GvHD) prophylaxis [11]. In five studies only primary
16 vaccinations were administered and in three studies the patients received a primary and a secondary
17 immunization.

18 **Results of individual studies**

19 **Safety**

20 Local or systemic vaccine reactions

21 Out of the 21,082 involved participants, local or systemic vaccine-associated adverse reactions were
22 observed in 280 patients (1.3%): 207/20,556 (1.0%) in the IMID group, 61/339 (18.0%) in the SOT
23 group and 12/187 in the BMT group (6.4%). Most frequent adverse reactions (n=269) were mild such
24 as injection-site pain, headache, fatigue, myalgia, fever, arthralgia, and nausea. Serious adverse

1 events (SAEs) were reported by 11 participants (Table 3).

2 In one study SAEs were reported in 11 IMID patients under prednisone treatment who received HZV
3 [12]. However, SAEs in the placebo group were as frequent as in the HZ-vaccinated group (6.6% vs.
4 5.7%). One of the SAEs in the HZ group was vaccine-related but the exact reason was not mentioned.
5 Six deaths occurred (three in placebo group and three in HZ group), of which none was judged to be
6 vaccine-related. The most frequently reported SAEs were respiratory, thoracic and mediastinal
7 disorders [12].

8 After receiving MMR, poliomyelitis, small pox, live typhoid and BCG vaccination in the IMID group,
9 there were no reported SAEs. Similarly, in the SOT and BMT group no SAEs were reported. Across
10 IMID, SOT and BMT patients, 17 articles did not document whether adverse events were observed.

11 Pathology through unrestricted proliferation of the attenuated strain

12

13 32 participants developed an infection through the vaccine strain. Overall, one infection occurred
14 after YFV, three after MMR vaccination, 20 after VV, five after HZV, one after live polio, one after
15 BCG, and one after smallpox vaccination.

16

17 **IMID**

18 In 12 of 20,556 (0.06%) IMID patients a vaccine-strain-related infection was reported (Table 3). One
19 49-year old female patient with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)
20 who started MTX and dexamethasone (dosage unknown) four days after the YFV developed a yellow
21 fever vaccine-associated viscerotropic disease (YEL-AVD) and died [13,14]. She received the
22 vaccination during a YF vaccination campaign in Peru, during which one particular vaccine lot was
23 found to be associated with a more than 20 times risk of YEL-AVD. Among 42,742 persons who
24 received a vaccine from this lot, five developed a YEL-AVD.

25 One juvenile idiopathic arthritis (JIA) patient with MTX experienced a rash and fever 20 days after a

1 primary MMR vaccination [15]. However, the rash was interpreted as disease-related [personal
2 communication with authors].

3 One patient with muco-cutaneous lymphnode syndrome under steroid therapy developed mild
4 varicella 11 days after immunization with VV [16], one SLE patient experienced a localized rash (<5
5 vesicles) after VV [17].

6 HZ and varicella zoster virus (VZV)-like rashes were seen in five patients after immunization with a
7 HZV [10,12,18]. One of them experienced a serious ophthalmic herpes zoster infection which was
8 determined to be vaccine-related by the investigator; however wild type virus and not vaccine strain
9 virus was identified by PCR [12]. Another patient who received a 15-day supply of prednisone two
10 months before being vaccinated, developed HZ seven days after vaccination [18]. One patient with
11 reactive arthritis under 50mg etanercept had a positive stool culture for poliovirus Sabin 1-like RNA
12 but without any symptoms after oral polio vaccination [19]. One infant whose mother was under
13 infliximab (IFX) treatment during pregnancy received the BCG vaccine at the age of three months and
14 developed disseminated BCG infection and died [20]. One patient with atopic eczema under topical
15 fluocinolone or betamethasone therapy developed smallpox-like vesicles after the smallpox
16 immunization and improved rapidly after receiving hyperimmune serum against vaccinia [21].

17 **SOT**

18 16/339 (4.7%) SOT patients had a vaccine-related infection (Table 3); 14 patients developed varicella
19 after VV within two to eight weeks. In all 14 patients it was only a moderate form of varicella without
20 complications [22–24]. Two patients had transient swelling of the parotid glands after mumps
21 immunization [25,26].

22 **BMT**

23 In the BMT group one patient developed HZ seven days after receiving the varicella vaccine (Table 3)
24 [27]. Symptoms resolved with treatment. In another study three patients developed a disseminated
25 rash within 2.5 weeks after VV [28]. The rash resolved without treatment. In all four cases there was

1 not clear whether the reaction had occurred in patients vaccinated less than or more than two years
2 after BMT.

3 Flare of underlying disease/ transplant rejection after vaccination

4 **IMID**

5 In a self-controlled case-series study, a 12.8 times (95%CI 4.28-38.13, $p < 0.001$) higher exacerbation
6 rate was reported in multiple sclerosis (MS) patients who received YFV under glatiramer acetate and
7 interferon treatment compared to time periods when these patients had not received YFV (“not-at-
8 risk-periods”) [29]. In a retrospective cohort study by Heijstek et al [30], no aggravation of disease
9 was registered in the MMR vaccinated JIA patients. In another study by Heijstek and colleagues [31],
10 the mean number of flares per patient did also not differ significantly between the vaccinated
11 patients and the control group. A boy with atopic dermatitis experienced an exacerbation of the skin
12 disease one week after BCG vaccination [32]. The exacerbation of the skin lesions resolved 3.5
13 months later after treatment. While 1/10 patients with inflammatory bowel disease (IBD) under
14 prednisolone 10mg had a flare 15 days after live typhoid immunization, 8/10 patients reported
15 improvement of abdominal symptoms after 90 days [33]. In three further studies improvement of
16 the basic diseases were reported. Two randomized controlled studies mentioned a significant
17 improvement of the psoriatic area in 83% of psoriasis patients after four doses of VV [34,35]. Less
18 patients in the control group showed a significant improvement. In a case report, two SLE patients
19 experienced improvement of their extrarenal manifestations after BCG vaccination [36].

20 **SOT**

21 In the SOT group, three cases of organ rejections were reported. One patient developed an episode
22 of acute rejection three weeks after measles vaccination. The other patient showed chronic rejection
23 at the time of vaccination and remained unchanged for one year [37]. Another single rejection
24 episode of the liver was reported, which occurred more than one year after a VV and was considered
25 as unassociated to immunization [38].

1 **BMT**

2 One child after autologous BMT had a relapse of her malignancy after MMR immunization, the time
3 point was unknown [39].

4 **Immunogenicity**

5 In 43 studies an immunogenicity assessment was performed: 23 (YF n=6, MMR n=3, VV n=9, HZ n=5)
6 in the IMID group, 12 (YF n=1, MMR n=7, VV n=4) in the SOT group and in all eight studies (MMR n=3,
7 VV n=5) in the BMT group. In the majority, an immunogenicity assessment was performed before
8 vaccination; the time points for the immunogenicity assessment varied from 15 days to 13 years after
9 vaccination.

10

11 **IMID**

12 In 19 articles the humoral immune response and in two articles the humoral and cellular response
13 was assessed. In two articles the test method was not documented.

14 YF-vaccinated IMID patients showed high seroconversion rates in four articles, which did not differ
15 between patients and controls [29,40–42]. Patients under therapy with short-term high dose
16 corticosteroids, long-term low-dose corticosteroids, glatiramer acetate, interferon gamma (INF- γ) or
17 MTX received a primary YFV. Only in one of these studies, patients who received transcutaneous
18 vaccination instead of subcutaneous vaccination demonstrated significantly lower YFV-specific T-cell
19 responses [40]. After YF revaccination under IFX (\pm MTX), 1/17 patients and 1/15 controls remained
20 seronegative [8]. In another study on rheumatic patients under various treatments a seropositivity of
21 87% was achieved after YF revaccination. Patients showed lower titers of neutralizing antibodies than
22 healthy individuals [43]. The patient with the lowest antibody titer had been administered 2mg
23 rituximab (RTX) four months before YF revaccination.

24

25 In one study, MMR-vaccinated JIA patients treated with low-dose MTX had lower levels of virus-
26 specific antibodies and IFN- γ producing T memory cells than healthy children [44]. The patients who

1 additionally received etanercept showed a decline of virus-specific IFN- γ producing T cells and IgG
2 antibodies were slightly increased. Kawasaki patients vaccinated against MMR within six months
3 after administration of intravenous immunoglobulin (IVIG) had lower IgG concentrations against
4 measles, mumps and rubella compared to controls [45]. Patients vaccinated later than nine months
5 after IVIG administration did not show any difference to controls. No significant differences in
6 humoral responses were observed between patients with and without MTX or biologics after MMR
7 vaccination [31].

8

9 In three studies with a limited sample size, VV showed good immunogenicity results in IMID patients
10 [16,46,47]. In two studies, SLE patients developed comparable VZV-specific antibody levels to
11 controls [17,48]. However the cellular responses were lower in SLE patients [17].

12 In three studies JIA showed lower seroconversion rates than controls [49–51]. In one study all 10
13 non-converters were under sole MTX therapy or received additional prednisone [49]. In another
14 study all four non-converters were under tumor necrosis factor inhibitor (TNFi) therapy [49]. In
15 contrary to tocilizumab (TCZ) treated patients, patients under IFX/MTX and etanercept had
16 insufficient responses [51]. In a report of six cases under treatment with mesalamine, olsalazine, 6-
17 mercaptopurine, and/or IFX extremely varying results were observed [52].

18

19 In three studies HZV showed a worse immune response in immunosuppressed patients than in the
20 immunocompetent group [53–55]. In a case report a patient with MS under fingolimod remained
21 seronegative after administration of HZV, even despite he had two clinical episodes of HZ infection
22 [54].

23 In a study 10 SLE patients under prednisone, hydroxychloroquine or MTX showed similar cellular
24 immune responses as controls, but the increase of antibody levels was lower [55]. In two studies
25 patients under treatment with steroids and further modifying agents achieved adequate antibody
26 levels after HZV [12,56].

1 **SOT**

2 In 10 studies the humoral and in two studies cellular and humoral tests were performed. A kidney
3 transplant recipient under CSA and mycophenolic acid vaccinated against YFV 19 years post-
4 transplant reached antibody titers within the lower range of those of controls [57].

5 The seroconversion after post-transplant vaccination showed generally higher rates for rubella
6 (range 70-100%) than for measles (44-100%), mumps (48-100%) and varicella (71%) [25,26,37,58-
7 61]. Patients were under various therapies including CSA, prednisone, azathioprine and TAC. In two
8 studies, the patients were also tested after a second or a third vaccination and showed higher
9 seroconversion rates afterwards [58,59].

10

11 The seroconversion rate after VV in SOT patients varied from 25 to 87% [22,25,26,58-60,62,63]. In a
12 study with patients under triple therapy with prednisone, CSA and azathioprine, 59% developed anti-
13 varicella antibodies within the first four to eight weeks after a primary vaccine dose [62]. By three to
14 six months after immunization, 85% were seropositive and at 24 months 76% of the antibody titers
15 remained positive. In two studies, patients under MMF, prednisone, CSA, TAC or sirolimus reached
16 similar seroconversion rates of 64-67% [60,63]. 87% of patients under CSA and TAC receiving one
17 dose of VV seroconverted and 86% had positive cellular responses [22].

18 Patients under TAC and CSA receiving a varicella revaccination one year after liver transplantation,
19 had seroconversion rates between 50% and 81% after re-immunization [26,58,59].

20 In a study all children (100%) reached seroconversion after one, two or three vaccinations [38]. After
21 the last vaccine dose 96.8% (31/32) of the children retained high-median antibody titers. In 20
22 patients, VZV-specific CD4+ T cell responses were compared pre- and post- immunization and they
23 showed a significant increase.

24

25 **BMT**

26 In four studies an immunogenicity assessment was performed by humoral tests, in one study by

1 cellular tests and in one study by humoral and cellular tests. In two BMT studies the test was
2 unspecified.

3 Three studies with patients who received an MMR immunization within 24 months after BMT
4 showed a higher seroconversion rate for rubella (86-100%) than for measles (33-46%) and mumps
5 (29-80%) [11,39,64]. It was observed that children seroconverted more frequently to measles if they
6 were immunized more than 15 months after BMT (35% prior to versus 78% after 15 months) [64].
7 Seroconversion rates were 86% for rubella, 43% for measles and 29% for mumps in patients treated
8 with calcineurin inhibitors and MMF after a primary MMR vaccine [11].

9 In another study, after a primary measles vaccine dose, all patients seroconverted and 78% remained
10 seropositive for at least 12 months [65]. However, only 44% of these patients were on
11 immunosuppressive drugs at the time of vaccination.

12 For varicella vaccination after BMT, seroconversion rates varied between 33 and 89% after a primary
13 VV [11,27,66,67]. In the study in which only 33% seroconversion was achieved, patients were under
14 GvHD-prophylaxis with calcineurin inhibitors and MMF. In the other studies patients were without
15 immunosuppressive treatment.

16

17 **Clinical protection of vaccines**

18 In the IMID group, 12/202 patients (6%) who received a VV nevertheless developed a varicella
19 infection or HZ. 8/19,630 patients (0.04%) receiving a HZV later had a HZ infection despite
20 vaccination. YF-, MMR-, Polio, BCG- and typhoid fever-vaccinated patients appeared to be protected
21 and did not develop an infection.

22 In the SOT group, 7/192 (3.6%) patients developed a varicella infection despite being vaccinated
23 against varicella. 2/38 (5.3%) in the BMT group developed varicella in spite of a VV. Patients in the
24 SOT and BMT group who were vaccinated against YF, MMR and BCG were protected against
25 infection. Follow-up periods for clinical protection varied between 6 weeks to 12.5 years.

26

1 **Discussion**

2 Whether live vaccines can be administered to immunocompromised patients is an often-
3 encountered problem by physicians caring for this specific patient group. On the one hand these
4 patients are especially vulnerable from infections (many of them vaccine-preventable) on the other
5 hand there is a potential risk of harming the patient by the administration of a vaccine containing an
6 attenuated vaccine strain, which has the theoretical potential to revert to the original pathogenic
7 form and to induce infection in the immunocompromised individual. Apart from infecting the
8 immunocompromised person, more vaccine-related side effects as well as re-activation of the
9 underlying disease is feared. Therefore this review summarizes available information in order to
10 inform the practitioner of currently available evidence by reviewing and giving an overview on
11 currently available literature on this topic.

12 Generally local and systemic reactions were mild. While they were rare in IMID patients (prevalence
13 of 1%), they occurred more frequently in BMT (6%) and SOT patients (18%). The percentages of
14 adverse events (AEs) appear low compared to AEs reported in the general population [68–71]. This is
15 most likely due to underreporting of AEs in our included studies.

16 Altogether, 11 SAEs due to local or systemic reactions including three deaths were reported;
17 however, none of the deaths was vaccine-associated. All reported SAEs occurred in IMID patients
18 after HZV. In the other vaccination groups, numbers of patients were low, thus SAEs may not have
19 been observed due to the limited sample sizes. Also in the literature local or systemic SAEs after live
20 vaccinations are extremely rare. For examples, anaphylactic reactions after YFV occur in 0.8-
21 1.8/100,000 administered doses and thrombocytopenia after MMR vaccination is estimated to occur
22 in one out of 30,000-40,000 administered MMR doses [72,73].

23 In the 2010 published recommendations on YFV on immunization practices of the Centers for Disease
24 Control and Prevention report on several YEL-AVD cases in individuals with underlying autoimmune
25 conditions: three patients with SLE, two with Addison's disease, one with Crohn's disease, one with

1 polymyalgia rheumatica and hypothyroidism, one with ulcerative colitis, and one with myasthenia
2 gravis [74]. In direct correspondence with one of the authors, she confirmed that a number of
3 viscerotropic diseases have occurred in persons with autoimmune diseases. However, it could not be
4 clarified whether these patients were on immunosuppressive or immunomodulatory therapy at the
5 time of YFV. Thus, it remains unclear how to interpret this information. The safety monitoring board
6 in Switzerland has not detected a severe infection with a vaccine strain in an immunosuppressed
7 patient between 2001 and May 2016 [personal communication].

8 Infections through vaccine strains were extremely rare. However, two of them were deadly. One
9 occurred in a patient with RA/SLE overlap who received YFV four days prior to commencement of
10 MTX/dexamethasone treatment. However, the administered vaccine lot was associated with a 20
11 times higher risk of YEL-AVD compared to other YFV lots. A fatal disseminated BCG infection was
12 reported upon vaccination of a three-month-old infant born to a mother under IFX treatment. Thus,
13 infants born to immunosuppressed mothers should be vaccinated with caution. The other vaccine-
14 associated infections were either self-limiting or resolved upon treatment.

15 Regarding reactivation of the underlying disease, apart from one article, no increase of flares of
16 underlying autoimmune conditions was encountered. One study detected a more than 12 times
17 elevated risk of MS exacerbation after YFV [29]. However, this self-controlled case series study was
18 criticized for methodological issues [75].

19 In SOT patients, one liver transplant rejection was reported three weeks after measles vaccination
20 [37]. Acute organ rejections can occur in around 15-25% of liver transplant recipients [76–78]. Thus it
21 is not surprising to see an acute organ rejection three weeks after measles vaccination (one of 271
22 liver transplant patients who received a live vaccine), which is most likely only timely but not causally
23 associated to vaccination. Details such as numbers on non-serious specific systemic and local
24 reactions were often not presented in the publications.

25

1 Immunogenicity data are difficult to interpret as a large variety of serological and cellular test
2 methods were used. YF (re)vaccinations appeared to be immunogenic in most patient groups. TNFi
3 and MTX therapy seemed to reduce immune responses after VV and HZ vaccination. This is in line
4 with studies on inactivated vaccines, such as pneumococcal and hepatitis A vaccine [79,80]. Rubella
5 vaccinations appeared more immunogenic than measles and mumps vaccination, which is also
6 known in non-immunosuppressed individuals [73]. For VV, one vaccine did often not suffice, but two
7 or more vaccine doses generally conferred satisfactory immunity.

8 Most studies included in this systematic review were conducted in a non-randomized, uncontrolled
9 and unblinded way and thus are prone to bias. Only eight of 64 included studies were RCTs. Only in
10 one study blinding of patients and study personnel was performed. However, as literature is
11 generally scarce on live vaccines in the immunosuppressed we included observational studies and
12 case reports as our aim was to compile all available evidence on live vaccinations in
13 immunosuppressed IMiD, SOT patients as well as BMT patients who received a live vaccine less than
14 two years after transplantation. Furthermore, this systematic review may have missed published
15 studies as the search was conducted in English. Even though we included grey literature, publication
16 bias may have limited the identifiable studies/case reports.

17

18 A YEL-AVD occurs in an estimated 0.4 of 100,000 administered vaccine doses [81]. In our identified
19 studies and case reports we found one YEL-AVD in a RA/SLE patient who was vaccinated with a
20 specific vaccine strain associated with a higher YEL-AVD risk. It is well possible that more YEL-AVDs
21 were simply missed/or have not occurred as patient numbers who received a live vaccine are
22 extremely low. Severe reactions or infections may only be discovered if a large number of patients
23 with these conditions receive live vaccines.

24

25

26

1 **Conclusion**

2 Overall, the identified data on live vaccinations in IMID and SOT patients on immunosuppressive
3 treatment as well as patients less than two years after BMT are not sufficiently robust to change the
4 currently available international vaccination recommendations which generally are very restrictive on
5 live vaccines under immunosuppression or shortly after BMT. Only eight randomized controlled trials
6 could be identified and all were conducted in IMID patients. However, patient groups, medications,
7 medication dosages and live vaccinations were diverse within these eight trials and generally patient
8 numbers were low.

9 From the available evidence we cannot conclude that live vaccines are safe altogether in
10 immunosuppressed IMID, SOT and when administered within two years after BMT. However, despite
11 the limitations discussed above it is re-assuring that in the examined patient groups serious side
12 effects or infections by the attenuated vaccine strain were extremely scarce after primary
13 vaccinations and revaccinations with the examined vaccines (MMR, YFV, VV, HZV, oral typhoid fever,
14 oral polio, BCG, smallpox).

15 We believe that our research of the existing literature is of help to the interested specialist
16 confronted with the decision process on whether to vaccinate an immunosuppressed patient. More
17 evidence regarding the safety and immunogenicity of live vaccinations in IMID and SOT patients
18 under various immunosuppressive therapies as well as in patients less than two years after BMT is
19 urgently needed. Vaccination recommendations need to be adapted on a regular basis, as more
20 scientific data regarding vaccination safety and efficacy, new vaccines as well as new
21 immunosuppressive therapies will become available.

22 **Funding**

23 This research did not receive any specific grant from funding agencies in the public, commercial, or
24 not-for-profit sectors.

1 **Conflic of Interest**

2 None

3 **Acknowledgements**

4 We would like to thank Erin Staples, Valeriu Toma (Swiss safety monitoring board) as well as the
5 contacted authors for sharing their experiences and information with us during the development of
6 this systematic review.

7 **Authorship**

8 All authors have made substantial contributions to the conception of the systematic review including
9 serach term definition. SB and VKJ performed eligibility assessment of articles based on titles, key
10 words, and abstracts independently. EC conducted the eligibility assessment based on the full article;
11 this was checked by SB and VKJ. EC performed the data extraction, which was checked by SB and VKJ.
12 All authors have made substantial contributions in the interpretation of the extracted data, drafting
13 of the systematic review and revising it critically for important intellectual content. All authors have
14 approved the final version before submission.

15

16

1 References

- 2 [1] Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal myeloencephalitis following yellow
3 fever vaccination in a case with HIV infection. *J Med Assoc Thai* 2002;85:131–4.
- 4 [2] Ninane J, Grymonprez A, Burtonboy G, Francois A, Cornu G. Disseminated BCG in HIV
5 infection. *Arch Dis Child* 1988;63:1268–9.
- 6 [3] Davis LE, Bodian D, Price D, Butler IJ, Vickers JH. Chronic progressive poliomyelitis secondary
7 to vaccination of an immunodeficient child. *N Engl J Med* 1977;297:241–5.
- 8 [4] Mitus A, Holloway A, Evans AE, Enders JF. Attenuated measles vaccine in children with acute
9 leukemia. *Am J Dis Child* 1962;103.
- 10 [5] Biétry F, Pitzurra R, Schwenkglens M, Meier CR. *Helsana-Arzneimittelreport* 2014.
- 11 [6] Vonkeman H, ten Napel C, Rasker H, van de Laar M. Disseminated primary varicella infection
12 during infliximab treatment. *J Rheumatol* 2004;31:2517–8.
- 13 [7] Takahashi E, Kurosaka D, Yoshida K, Yanagimachi M, Kingetsu I, Yamada A. [Onset of modified
14 measles after etanercept treatment in rheumatoid arthritis]. *Nihon Rinsho Meneki Gakkai*
15 *Kaishi* 2010;33:37–41.
- 16 [8] Scheinberg M, Guedes-Barbosa LS, Manguera C, Rosseto EA, Mota L, Oliveira AC, et al.
17 Yellow fever revaccination during infliximab therapy. *Arthritis Care Res (Hoboken)*
18 2010;62:896–8.
- 19 [9] Carpenter PA, Englund JA. How I vaccinate blood and marrow transplant recipients. *Blood*
20 2016;127.
- 21 [10] Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, et al. Association between vaccination
22 for herpes zoster and risk of herpes zoster infection among older patients with selected
23 immune-mediated diseases. *JAMA* 2012;308:43–9.
- 24 [11] Small TN, Iovino CS, Abboud M, Lubin M, Papadopoulos E, Scaradavou A, et al. Vaccine
25 response in recipients of HLA mismatched unrelated double unit cord blood transplantation
26 (CBT). *ASH Annu Meet Abstr* 2010;116.
- 27 [12] Russell AF, Parrino J, Fisher CL, Spieler W, Stek JE, Coll KE, et al. Safety, tolerability, and
28 immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids. *Vaccine*
29 2015;33:3129–34.
- 30 [13] Meeting of Global Advisory Committee on Vaccine Safety, 18-19 June 2008. *Relev*
31 *Épidémiologique Hebd / Sect D'hygiène Du Secrétariat La Société Des Nations = Wkly*
32 *Epidemiol Rec / Heal Sect Secr Leag Nations* 2008;83:287–92.
- 33 [14] Whittembury A, Ramirez G, Hernández H, Ropero AM, Waterman S, Ticona M, et al.
34 Viscerotropic disease following yellow fever vaccination in Peru. *Vaccine* 2009;27:5974–81.
- 35 [15] Pileggi GS, Terreri MTRA, Barbosa CMPL, Ferriani VPL. Measles, mumps and rubella
36 vaccination safety in patients with juvenile rheumatic diseases taking immunosuppressive
37 drugs. *Ann Rheum Dis* 2012;71:260–260.
- 38 [16] Ueda K, Yamada I, Goto M, Nanri T, Fukuda H, Katsuta M, et al. Use of a live varicella vaccine
39 to prevent the spread of varicella in handicapped or immunosuppressed children including
40 MCLS (muco-cutaneous lymphnode syndrome) patients in hospitals. *Biken J* 1977;20:117–23.

- 1 [17] Barbosa CMPL, Terreri MTRA, Rosário PO, de Moraes-Pinto MI, Silva CAA, Hilário MOE.
2 Immune response and tolerability of varicella vaccine in children and adolescents with
3 systemic lupus erythematosus previously exposed to varicella-zoster virus. *Clin Exp Rheumatol*
4 n.d.;30:791–8.
- 5 [18] Zhang J, Delzell E, Xie F, Baddley JW, Spettell C, McMahan RM, et al. The use, safety, and
6 effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune
7 diseases: a longitudinal observational study. *Arthritis Res Ther* 2011;13:R174.
- 8 [19] Badsha H, Daher M, Edwards CJ. Live polio vaccine exposure while receiving anti-TNF therapy
9 for reactive arthritis. *Int J Rheum Dis* 2010;13:184–6.
- 10 [20] Cheent K, Nolan J, Shariq S, Kiho L, Pal A, Arnold J. Case Report: Fatal case of disseminated
11 BCG infection in an infant born to a mother taking infliximab for Crohn's disease. *J Crohns*
12 *Colitis* 2010;4:603–5.
- 13 [21] Gundersen SG, Bjorvatn B. Vaccinia and topical steroids: a case report. *Acta Derm Venereol*
14 1980;60:445–7.
- 15 [22] Weinberg A, Horslen SP, Kaufman SS, Jesser R, Devoll-Zabrocki A, Fleckten BL, et al. Safety
16 and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant
17 recipients. *Am J Transplant* 2006;6:565–8.
- 18 [23] Levitsky J, Te HS, Faust TW, Cohen SM. Varicella infection following varicella vaccination in a
19 liver transplant recipient. *Am J Transplant* 2002;2:880–2.
- 20 [24] Kraft JN, Shaw JC. Varicella infection caused by Oka strain vaccine in a heart transplant
21 recipient. *Arch Dermatol* 2006;142:943–5.
- 22 [25] Shinjoh M, Miyairi I, Hoshino K, Takahashi T, Nakayama T. Effective and safe immunizations
23 with live-attenuated vaccines for children after living donor liver transplantation. *Vaccine*
24 2008;26:6859–63.
- 25 [26] Shinjoh M, Hoshino K, Takahashi T, Nakayama T. Updated data on effective and safe
26 immunizations with live-attenuated vaccines for children after living donor liver
27 transplantation. *Vaccine* 2015;33:701–7.
- 28 [27] Kussmaul SC, Horn BN, Dvorak CC, Abramovitz L, Cowan MJ, Weintrub PS. Safety of the live,
29 attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs. *Bone Marrow*
30 *Transplant* 2010;45:1602–6.
- 31 [28] Chou JF, Kernan NA, Prockop S, Heller G, Scaradavou A, Kobos R, Knowles MA, Papadopoulos
32 EB, Casson A, Copeland C, Torok-Castanza J, Zakak N, Ruggiero J ST. Safety and
33 immunogenicity of the live attenuated varicella vaccine following T replete or T cell depleted
34 related and unrelated allogeneic hematopoietic cell transplantation (allHCT). *Biol Blood*
35 *Marrow Transplant* 2011;17:1708–13.
- 36 [29] Farez MF, Correale J. Yellow fever vaccination and increased relapse rate in travelers with
37 multiple sclerosis. *Arch Neurol* 2011;68:1267–71.
- 38 [30] Heijstek MW, Pileggi GCS, Zonneveld-Huijssoon E, Armbrust W, Hoppenreijns EPAH, Uiterwaal
39 CSPM, et al. Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis.
40 *Ann Rheum Dis* 2007;66:1384–7.
- 41 [31] Heijstek MW, Kamphuis S, Armbrust W, Swart J, Gorter S, de Vries LD, et al. Effects of the live
42 attenuated measles-mumps-rubella booster vaccination on disease activity in patients with

- 1 juvenile idiopathic arthritis: a randomized trial. *JAMA* 2013;309:2449–56.
- 2 [32] Dalton SJ, Haeney MR, Patel L, David TJ. Exacerbation of atopic dermatitis after bacillus
3 Calmette-Guérin vaccination. *J R Soc Med* 1998;91:133–4.
- 4 [33] Nysaeter G, Berstad A. Live typhoid vaccine for IBD-patients - well tolerated and with possible
5 therapeutic effect. *Drug Target Insights* 2008;3:119–23.
- 6 [34] El-Darouti MA, Hegazy RA, Abdel Hay RM, Abdel Halim DM. Live attenuated varicella vaccine:
7 a new effective adjuvant weapon in the battlefield against severe resistant psoriasis, a pilot
8 randomized controlled trial. *J Am Acad Dermatol* 2012;66:511–3.
- 9 [35] El-Darouti MA, Hegazy RA, Abdel Hay RM, Rashed LA. Study of T helper (17) and T regulatory
10 cells in psoriatic patients receiving live attenuated varicella vaccine therapy in a randomized
11 controlled trial. *Eur J Dermatol* 24:464–9.
- 12 [36] Guzman RR, Villazor RP, Canete RR, Eslava AG, Cornejo SA, Picazo EA, et al. Beneficial role of
13 bacille calmette-guerin (BCG) vaccination in the management of systemic lupus
14 erythematosus: a report of three cases. *Philipp J Intern Med* 1983;21:3329–34.
- 15 [37] Rand EB, McCarthy CA, Whittington PF. Measles vaccination after orthotopic liver
16 transplantation. *J Pediatr* 1993;123:87–9.
- 17 [38] Posfay-Barbe KM, Pittet LF, Sottas C, Grillet S, Wildhaber BE, Rodriguez M, et al. Varicella-
18 zoster immunization in pediatric liver transplant recipients: safe and immunogenic. *Am J*
19 *Transplant* 2012;12:2974–85.
- 20 [39] Pauksen K, Duraj V, Ljungman P, Sjölin J, Oberg G, Lönnnerholm G, et al. Immunity to and
21 immunization against measles, rubella and mumps in patients after autologous bone marrow
22 transplantation. *Bone Marrow Transplant* 1992;9:427–32.
- 23 [40] Slifka MK, Leung DYM, Hammarlund E, Raué H-P, Simpson EL, Tofte S, et al. Transcutaneous
24 yellow fever vaccination of subjects with or without atopic dermatitis. *J Allergy Clin Immunol*
25 2014;133:439–47.
- 26 [41] Kernéis S, Launay O, Ancelle T, Iordache L, Naneix-Laroche V, Méchai F, et al. Safety and
27 immunogenicity of yellow fever 17D vaccine in adults receiving systemic corticosteroid
28 therapy: an observational cohort study. *Arthritis Care Res (Hoboken)* 2013;65:1522–8.
- 29 [42] Stuhec M. Yellow fever vaccine used in a psoriatic arthritis patient treated with
30 methotrexate: a case report. *Acta Dermatovenerologica Alpina, Pannonica, Adriat*
31 2014;23:63–4.
- 32 [43] Oliveira AC V, Mota LMH, Santos-Neto LL, Simões M, Martins-Filho OA, Tauil PL.
33 Seroconversion in patients with rheumatic diseases treated with immunomodulators or
34 immunosuppressants, who were inadvertently revaccinated against yellow fever. *Arthritis*
35 *Rheumatol (Hoboken, NJ)* 2015;67:582–3.
- 36 [44] Borte S, Liebert UG, Borte M, Sack U. Efficacy of measles, mumps and rubella revaccination in
37 children with juvenile idiopathic arthritis treated with methotrexate and etanercept.
38 *Rheumatology (Oxford)* 2009;48:144–8.
- 39 [45] Tacke CE, Smits GP, van der Klis FRM, Kuipers IM, Zaaijer HL, Kuijpers TW. Reduced serologic
40 response to mumps, measles, and rubella vaccination in patients treated with intravenous
41 immunoglobulin for Kawasaki disease. *J Allergy Clin Immunol* 2013;131:1701–3.

- 1 [46] Katsushima N, Yazaki N, Sakamoto M, Fujiyama J, Nakagawa M, Okuyama Y, et al. Application
2 of a live varicella vaccine to hospitalized children and its follow-up study. *Biken J* 1982;25:29–
3 42.
- 4 [47] Speth Fabian, Haas Johannes Peter, Loeber Susanne, Hinze Claas. Varicella vaccination in
5 patients with pediatric rheumatic diseases receiving immunosuppression: Proposal of a pre-
6 vaccination checklist to ensure safety. *Arthritis Rheumatol* 2015;74:94.
- 7 [48] Barbosa CMPL, Terreri MTRA, Len Claudio A, de Moraes-Pinto MI, Rosário P, Hilário MOE.
8 Varicella vaccine in children and adolescents with systemic lupus erythematosus (SLE)
9 Immunogenicity and Safety. *Arthritis Rheum* 2009;60:1521.
- 10 [49] Pileggi GS, de Souza CBS, Ferriani VPL. Safety and immunogenicity of varicella vaccine in
11 patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids.
12 *Arthritis Care Res (Hoboken)* 2010;62:1034–9.
- 13 [50] Pileggi GCS, de Souza CBS, Ferriani VPL. Safety and Efficacy of varicella vaccine in patients
14 with juvenile rheumatic diseases: a five years experience. *Ann Rheum Dis* 2012;71:430.
- 15 [51] Toplak N, Avčin T. Long-term safety and efficacy of varicella vaccination in children with
16 juvenile idiopathic arthritis treated with biologic therapy. *Vaccine* 2015;33:4056–9.
- 17 [52] Lu Y, Bousvaros A. Varicella vaccination in children with inflammatory bowel disease receiving
18 immunosuppressive therapy. *J Pediatr Gastroenterol Nutr* 2010;50:562–5.
- 19 [53] Farraye F, Wasan S, Berg A, Ganley-Leal L, Liang YM. Immune response and safety of herpes
20 zoster vaccine in IBD patients on methotrexate or thiopurines. 77th Annu. Sci. Meet. of Am.
21 Coll. Gastroenterol. Las Vegas, USA, 2012.
- 22 [54] Berger JR. Varicella vaccination after fingolimod: A case report. *Mult Scler Relat Disord*
23 2013;2:391–4.
- 24 [55] Guthridge JM, Cogman A, Merrill JT, Macwana S, Bean KM, Powe T, et al. Herpes zoster
25 vaccination in SLE: a pilot study of immunogenicity. *J Rheumatol* 2013;40:1875–80.
- 26 [56] Mc Graw C, Inglese M, Petracca M, Hannigan C, Miller A. An open-label observational pilto
27 study to evaluate the safety and immunogenicity of the herpes zoster vaccina in patients with
28 multiple sclerosis. *Neurology* 2013;80:p01.181.
- 29 [57] Slifka MK, Hammarlund E, Lewis MW, Poore EA, Hanifin JM, Marr KA, et al. Antiviral immune
30 response after live yellow fever vaccination of a kidney transplant recipient treated with IVIG.
31 *Transplantation* 2013;95:e59–61.
- 32 [58] Kano H, Mizuta K, Sakakihara Y, Kato H, Miki Y, Shibuya N, et al. Efficacy and safety of
33 immunization for pre- and post- liver transplant children. *Transplantation* 2002;74:543–50.
- 34 [59] Kawano Y, Suzuki M, Kawada J, Kimura H, Kamei H, Ohnishi Y, et al. Effectiveness and safety
35 of immunization with live-attenuated and inactivated vaccines for pediatric liver
36 transplantation recipients. *Vaccine* 2015;33:1440–5.
- 37 [60] Khan S, Erlichman J, Rand EB. Live virus immunization after orthotopic liver transplantation.
38 *Pediatr Transplant* 2006;10:78–82.
- 39 [61] Gerner P, Ballauff A, Abramow U, Lainka E, Gierenz N, Hoyer PF. Immunization with the
40 measles-mumps-rubella vaccine in children before and after liver transplantation. *Ger J*
41 *Gastroenterol* 2009;47:P098.

- 1 [62] Zamora I, Simon JM, Da Silva ME, Piqueras AI. Attenuated varicella virus vaccine in children
2 with renal transplants. *Pediatr Nephrol* 1994;8:190–2.
- 3 [63] Chaves T do SS, Lopes MH, de Souza VAUF, Dos Santos SDS, Pereira LM, Reis AD, et al.
4 Seroprevalence of antibodies against varicella-zoster virus and response to the varicella
5 vaccine in pediatric renal transplant patients. *Pediatr Transplant* 2005;9:192–6.
- 6 [64] Shaw PJ, Bleakley M, Burgess M. Safety of early immunization against
7 measles/mumps/rubella after bone marrow transplantation. *Blood* 2002;99:3486.
- 8 [65] Machado CM, de Souza V a UF, Sumita LM, da Rocha IF, Dulley FL, Pannuti CS. Early measles
9 vaccination in bone marrow transplant recipients. *Bone Marrow Transplant* 2005;35:787–91.
- 10 [66] Sauerbrei A, Prager J, Hengst U, Zintl F, Wutzler P. Varicella vaccination in children after bone
11 marrow transplantation. *Bone Marrow Transplant* 1997;20:381–3.
- 12 [67] Chou JF, Kernan NA, Prockop S, Heller G, Scaradavou A, Kobos R, et al. Safety and
13 immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted
14 related and unrelated allogeneic hematopoietic cell transplantation (alloHCT). *Biol Blood
15 Marrow Transplant* 2011;17:1708–13.
- 16 [68] Swissmedic. Product information Stamaril®. January 2013 2013.
- 17 [69] Swissmedic. Product information Priorix®. Oct 2015 2015.
- 18 [70] Swissmedic. Product information Varilrix®. July 2015 2015.
- 19 [71] Swissmedic. Product information ZOSTAVAX®. Febr 2016 2016.
- 20 [72] World Health Organization. Information Sheet Observed Rate of Vaccine Reactions Measles,
21 Mumps and Rubella Vaccines n.d.
- 22 [73] Plotkin SA, Orenstein WA, Offit PA. *Vaccines*. 6th ed. Philadelphia, Pennsylvania: Elsevier
23 Saunders; 2012.
- 24 [74] Staples JE, Gershman MD, Fischer M. Yellow Fever Vaccine: Recommendations of the
25 Advisory Committee on Immunization Practices (ACIP). *Morb Mortal Wkly Rep* 2010.
- 26 [75] Pool V, Gordon DM, Decker M. Methodological issues with the risk of relapse study in
27 patients with multiple sclerosis after yellow fever vaccination. *Arch Neurol* 2012;69:144;
28 author reply 144–5.
- 29 [76] Maluf DG, Stravitz RT, Cotterell AH, Posner MP, Nakatsuka M, Sterling RK, et al. Adult living
30 donor versus deceased donor liver transplantation: a 6-year single center experience. *Am J
31 Transplant* 2005;5:149–56.
- 32 [77] Gruttadauria S, Vasta F, Mandalà L, Cintonino D, Piazza T, Spada M, et al. Basiliximab in a
33 triple-drug regimen with tacrolimus and steroids in liver transplantation. *Transplant Proc*
34 37:2611–3.
- 35 [78] Ma Y, Wang G-D, He X-S, Li J-L, Zhu X-F, Hu R. Clinical and pathological analysis of acute
36 rejection following orthotopic liver transplantation. *Chin Med J (Engl)* 2009;122:1400–3.
- 37 [79] Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jonsson G, Geborek P. Influence of
38 methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal
39 polysaccharide vaccine in patients with rheumatoid arthritis. *Rheumatol* 2006;45:106–11.

- 1 [80] Askling HH, Rombo L, van Vollenhoven R, Hallén I, Thörner Å, Nordin M, et al. Hepatitis A
2 vaccine for immunosuppressed patients with rheumatoid arthritis: A prospective, open-label,
3 multi-centre study. *Travel Med Infect Dis*
4 2014;<http://dx.doi.org/10.1016/j.tmaid.2014.01.005>.
- 5 [81] Centers for Disease Control and Prevention. Notes from the Field: Fatal Yellow Fever
6 Vaccine–Associated Viscerotropic Disease — Oregon, September 2014. *Morb Mortal Wkly*
7 *Rep* 2015;March 20, 2015 / 64(10);279–81.
- 8